vs
Side-by-side financial comparison of Citius Pharmaceuticals, Inc. (CTXR) and TON Strategy Co (TONX). Click either name above to swap in a different company.
TON Strategy Co is the larger business by last-quarter revenue ($5.7M vs $3.9M, roughly 1.5× Citius Pharmaceuticals, Inc.). Citius Pharmaceuticals, Inc. runs the higher net margin — -238.2% vs -3968.6%, a 3730.4% gap on every dollar of revenue.
Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing innovative prescription therapies addressing unmet medical needs across critical care, oncology, anti-infective treatment, and supportive care segments, primarily serving the U.S. healthcare market.
CTXR vs TONX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.9M | $5.7M |
| Net Profit | $-9.4M | $-227.9M |
| Gross Margin | 80.0% | 64.3% |
| Operating Margin | -228.7% | -159.2% |
| Net Margin | -238.2% | -3968.6% |
| Revenue YoY | — | 694.2% |
| Net Profit YoY | 8.6% | -7047.9% |
| EPS (diluted) | $-0.38 | $-3.89 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.9M | $5.7M | ||
| Q3 25 | — | $3.6M | ||
| Q2 25 | — | $2.1M | ||
| Q1 25 | — | $1.3M | ||
| Q4 24 | — | $723.0K | ||
| Q4 22 | — | $-5.1M | ||
| Q2 22 | — | $2.4M | ||
| Q1 22 | — | $2.7M |
| Q4 25 | $-9.4M | $-227.9M | ||
| Q3 25 | — | $84.3M | ||
| Q2 25 | — | $-2.4M | ||
| Q1 25 | — | $-2.6M | ||
| Q4 24 | — | $-3.2M | ||
| Q4 22 | — | $-16.0M | ||
| Q2 22 | — | $-6.4M | ||
| Q1 22 | — | $-7.0M |
| Q4 25 | 80.0% | 64.3% | ||
| Q3 25 | — | 75.4% | ||
| Q2 25 | — | 71.2% | ||
| Q1 25 | — | 73.4% | ||
| Q4 24 | — | 81.5% | ||
| Q4 22 | — | — | ||
| Q2 22 | — | 65.2% | ||
| Q1 22 | — | 63.8% |
| Q4 25 | -228.7% | -159.2% | ||
| Q3 25 | — | -601.5% | ||
| Q2 25 | — | -138.2% | ||
| Q1 25 | — | -203.8% | ||
| Q4 24 | — | -513.1% | ||
| Q4 22 | — | — | ||
| Q2 22 | — | -200.3% | ||
| Q1 22 | — | -271.5% |
| Q4 25 | -238.2% | -3968.6% | ||
| Q3 25 | — | 2336.8% | ||
| Q2 25 | — | -111.9% | ||
| Q1 25 | — | -196.5% | ||
| Q4 24 | — | -440.9% | ||
| Q4 22 | — | 315.6% | ||
| Q2 22 | — | -265.7% | ||
| Q1 22 | — | -259.7% |
| Q4 25 | $-0.38 | $-3.89 | ||
| Q3 25 | — | $2.23 | ||
| Q2 25 | — | $-1.79 | ||
| Q1 25 | — | $-2.51 | ||
| Q4 24 | — | $10.41 | ||
| Q4 22 | — | — | ||
| Q2 22 | — | $-2.63 | ||
| Q1 22 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.7M | $39.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $80.0M | $406.5M |
| Total Assets | $140.4M | $411.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $7.7M | $39.5M | ||
| Q3 25 | — | $53.9M | ||
| Q2 25 | — | $10.4M | ||
| Q1 25 | — | $12.2M | ||
| Q4 24 | — | $12.5M | ||
| Q4 22 | — | $2.4M | ||
| Q2 22 | — | $5.5M | ||
| Q1 22 | — | $3.7M |
| Q4 25 | $80.0M | $406.5M | ||
| Q3 25 | — | $639.1M | ||
| Q2 25 | — | $19.4M | ||
| Q1 25 | — | $14.6M | ||
| Q4 24 | — | $16.2M | ||
| Q4 22 | — | $5.2M | ||
| Q2 22 | — | $23.5M | ||
| Q1 22 | — | $15.8M |
| Q4 25 | $140.4M | $411.2M | ||
| Q3 25 | — | $661.9M | ||
| Q2 25 | — | $23.7M | ||
| Q1 25 | — | $18.4M | ||
| Q4 24 | — | $20.6M | ||
| Q4 22 | — | $24.5M | ||
| Q2 22 | — | $40.4M | ||
| Q1 22 | — | $38.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-13.0M | $-8.0M |
| Free Cash FlowOCF − Capex | — | $-8.0M |
| FCF MarginFCF / Revenue | — | -139.3% |
| Capex IntensityCapex / Revenue | — | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-20.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-13.0M | $-8.0M | ||
| Q3 25 | — | $-9.4M | ||
| Q2 25 | — | $-2.3M | ||
| Q1 25 | — | $-1.1M | ||
| Q4 24 | — | $-1.9M | ||
| Q4 22 | — | $-3.4M | ||
| Q2 22 | — | $-5.1M | ||
| Q1 22 | — | $-5.9M |
| Q4 25 | — | $-8.0M | ||
| Q3 25 | — | $-9.4M | ||
| Q2 25 | — | $-2.3M | ||
| Q1 25 | — | $-1.1M | ||
| Q4 24 | — | $-2.0M | ||
| Q4 22 | — | — | ||
| Q2 22 | — | — | ||
| Q1 22 | — | — |
| Q4 25 | — | -139.3% | ||
| Q3 25 | — | -261.4% | ||
| Q2 25 | — | -107.8% | ||
| Q1 25 | — | -87.0% | ||
| Q4 24 | — | -279.9% | ||
| Q4 22 | — | — | ||
| Q2 22 | — | — | ||
| Q1 22 | — | — |
| Q4 25 | — | 0.1% | ||
| Q3 25 | — | 0.4% | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | 5.1% | ||
| Q4 24 | — | 22.1% | ||
| Q4 22 | — | — | ||
| Q2 22 | — | — | ||
| Q1 22 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -0.11× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q4 22 | — | — | ||
| Q2 22 | — | — | ||
| Q1 22 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTXR
Segment breakdown not available.
TONX
| Market Live | $4.8M | 83% |
| Other | $960.0K | 17% |
